






































































































































Alternating	magnetic	field	(AMF)	 Membrane	Protein	 In-vivo	 Breast	 [114,	115]	
Gold	Nanoparticles	
(AuNPs)	
Laser	light	 EGFR	 In-vitro	 Oral	Squamous	Cell	carcinoma	 [116]	Mucin-7	 In-vitro	 Urothelial	Cells	 [117]	Near-Infrared	(NIR)	light	 TROP-2	 In-vitro	 Cervical	Cancer	 [118]	EGFR	 In-vitro	 Oral	Squamous	Cell	carcinoma	 [119]	Short-wave	radio	frequency	(RF)	energy	 EGFR	 In-vivo	 Pancreatic	 [120,	121]	
Carbon	Nanotubes	
(CNTs)	
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